Skip to content

PK(Pharmacokinetic) Papyrus Covered Coronary Stent System

PK(Pharmacokinetic) Papyrus Covered Coronary Stent System

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06223633
Enrollment
41
Registered
2024-01-25
Start date
2023-08-10
Completion date
2028-08-01
Last updated
2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease

Brief summary

The PK Papyrus Covered Coronary Stent System is a coronary stent being used at Methodist Dallas Medical Center for patients with coronary perforations.

Detailed description

The FDA has approved the PK Papyrus Covered Coronary Stent System for use in patients being treated for acute perforations of native coronary arteries and coronary bypass grafts in vessels ranging from 2.5 to 5.0 mm in diameter, under a Humanitarian Device Exemption (HDE #H170004). Methodist Dallas Medical Center will use this device for treating the above-described patient population.

Interventions

DEVICEPK Papyrus Covered Coronary Stent System

PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter

Exclusion criteria

* Patients in whom antiplatelet agents or anticoagulation therapy is contraindicated. * Patients with a known allergy or hypersensitivity to amorphous silicon carbide or any other compound of the system (siloxane-based polyurethane, L-605 cobalt chromium alloy including tungsten and nickel). * Lesions that cannot be reached or treated with the system. * Lesions with threatened or abrupt closure during attempted pre-dilation prior to stent implantation. * Risk of treatment-related occlusion of vital coronary artery side branches. * Uncorrected bleeding disorders. * Allergy to contrast media.

Design outcomes

Primary

MeasureTime frameDescription
Determining the number of the unanticipated adverse events related to the use of PK Papyrus Coronary Stent Graft SystemUp to 10 yearsNumber of patients with PK Papyrus being treated for acute perforations of native coronary arteries and bypass grafts in vessels.
Number of patients with the device10 yearsnumber of patients with success coronary artery and bypass grafts

Countries

United States

Contacts

CONTACTColette Ngo Ndjom, M.S.
clinicalresearch@mhd.com214-947-1279
CONTACTZaid Haddadin, M.S.
clinicalresearch@mhd.com214-947-1280
PRINCIPAL_INVESTIGATORLuis Bowen, M.D.

The Methodist Hospital Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026